vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and WESTWOOD HOLDINGS GROUP INC (WHG). Click either name above to swap in a different company.

WESTWOOD HOLDINGS GROUP INC is the larger business by last-quarter revenue ($27.1M vs $19.6M, roughly 1.4× STANDARD BIOTOOLS INC.). WESTWOOD HOLDINGS GROUP INC runs the higher net margin — 6.8% vs -177.4%, a 184.2% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -41.7%). WESTWOOD HOLDINGS GROUP INC produced more free cash flow last quarter ($18.8M vs $-23.1M). Over the past eight quarters, WESTWOOD HOLDINGS GROUP INC's revenue compounded faster (9.2% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Westwood Studios, Inc. was an American video game developer based in Las Vegas, Nevada. It was founded by Brett Sperry and Louis Castle in 1985 as Brelous Software, but got changed after 2 months into Westwood Associates and was renamed to Westwood Studios when Virgin Games bought the company in 1992. The company was bought by Electronic Arts alongside Virgin Interactive's North American operations in 1998. In January 2003, it was announced that Westwood, alongside Westwood Pacific, would be ...

LAB vs WHG — Head-to-Head

Bigger by revenue
WHG
WHG
1.4× larger
WHG
$27.1M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+30.2% gap
LAB
-11.5%
-41.7%
WHG
Higher net margin
WHG
WHG
184.2% more per $
WHG
6.8%
-177.4%
LAB
More free cash flow
WHG
WHG
$41.9M more FCF
WHG
$18.8M
$-23.1M
LAB
Faster 2-yr revenue CAGR
WHG
WHG
Annualised
WHG
9.2%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
WHG
WHG
Revenue
$19.6M
$27.1M
Net Profit
$-34.7M
$1.8M
Gross Margin
48.5%
Operating Margin
-168.5%
8.0%
Net Margin
-177.4%
6.8%
Revenue YoY
-11.5%
-41.7%
Net Profit YoY
-28.8%
-50.5%
EPS (diluted)
$-0.09
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
WHG
WHG
Q4 25
$27.1M
Q3 25
$19.6M
$24.3M
Q2 25
$21.8M
$23.1M
Q1 25
$40.8M
$23.3M
Q4 24
$46.5M
Q3 24
$22.1M
$23.7M
Q2 24
$22.5M
$22.7M
Q1 24
$45.5M
$22.7M
Net Profit
LAB
LAB
WHG
WHG
Q4 25
$1.8M
Q3 25
$-34.7M
$3.7M
Q2 25
$-33.5M
$1.0M
Q1 25
$-26.0M
$478.0K
Q4 24
$3.7M
Q3 24
$-26.9M
$-1.2M
Q2 24
$-45.7M
$-378.0K
Q1 24
$-32.2M
$50.0K
Gross Margin
LAB
LAB
WHG
WHG
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
WHG
WHG
Q4 25
8.0%
Q3 25
-168.5%
8.3%
Q2 25
-118.1%
3.8%
Q1 25
-80.8%
-0.3%
Q4 24
10.0%
Q3 24
-120.9%
-2.1%
Q2 24
-134.5%
-18.4%
Q1 24
-132.2%
12.9%
Net Margin
LAB
LAB
WHG
WHG
Q4 25
6.8%
Q3 25
-177.4%
15.4%
Q2 25
-153.7%
4.5%
Q1 25
-63.8%
2.1%
Q4 24
14.5%
Q3 24
-122.0%
-5.0%
Q2 24
-203.3%
-1.7%
Q1 24
-70.6%
0.2%
EPS (diluted)
LAB
LAB
WHG
WHG
Q4 25
$0.21
Q3 25
$-0.09
$0.41
Q2 25
$-0.09
$0.12
Q1 25
$-0.07
$0.05
Q4 24
$0.45
Q3 24
$-0.07
$-0.15
Q2 24
$-0.12
$-0.05
Q1 24
$-0.27
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
WHG
WHG
Cash + ST InvestmentsLiquidity on hand
$129.4M
$47.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$125.6M
Total Assets
$539.6M
$162.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
WHG
WHG
Q4 25
$47.7M
Q3 25
$129.4M
$41.3M
Q2 25
$158.6M
$35.2M
Q1 25
$150.9M
$29.1M
Q4 24
$46.5M
Q3 24
$210.6M
$48.3M
Q2 24
$269.8M
$44.1M
Q1 24
$287.1M
$46.6M
Total Debt
LAB
LAB
WHG
WHG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
WHG
WHG
Q4 25
$125.6M
Q3 25
$399.7M
$123.9M
Q2 25
$424.5M
$122.4M
Q1 25
$454.6M
$121.4M
Q4 24
$120.3M
Q3 24
$489.3M
$120.4M
Q2 24
$510.3M
$120.5M
Q1 24
$577.3M
$123.8M
Total Assets
LAB
LAB
WHG
WHG
Q4 25
$162.3M
Q3 25
$539.6M
$154.0M
Q2 25
$557.0M
$146.3M
Q1 25
$579.6M
$135.0M
Q4 24
$150.0M
Q3 24
$681.5M
$151.5M
Q2 24
$708.7M
$147.4M
Q1 24
$777.7M
$149.0M
Debt / Equity
LAB
LAB
WHG
WHG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
WHG
WHG
Operating Cash FlowLast quarter
$-22.2M
$18.9M
Free Cash FlowOCF − Capex
$-23.1M
$18.8M
FCF MarginFCF / Revenue
-118.1%
69.5%
Capex IntensityCapex / Revenue
4.5%
0.3%
Cash ConversionOCF / Net Profit
10.29×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
WHG
WHG
Q4 25
$18.9M
Q3 25
$-22.2M
$8.5M
Q2 25
$-20.7M
$7.3M
Q1 25
$-30.3M
$-4.9M
Q4 24
$21.1M
Q3 24
$-27.9M
$529.0K
Q2 24
$-39.0M
$3.6M
Q1 24
$-62.5M
$8.1M
Free Cash Flow
LAB
LAB
WHG
WHG
Q4 25
$18.8M
Q3 25
$-23.1M
$8.5M
Q2 25
$-22.6M
Q1 25
$-35.3M
$-4.9M
Q4 24
$21.0M
Q3 24
$-30.1M
$519.0K
Q2 24
$-41.0M
$3.5M
Q1 24
$-63.3M
$8.1M
FCF Margin
LAB
LAB
WHG
WHG
Q4 25
69.5%
Q3 25
-118.1%
34.8%
Q2 25
-103.6%
Q1 25
-86.6%
-21.1%
Q4 24
45.2%
Q3 24
-136.4%
2.2%
Q2 24
-182.2%
15.6%
Q1 24
-138.9%
35.8%
Capex Intensity
LAB
LAB
WHG
WHG
Q4 25
0.3%
Q3 25
4.5%
0.3%
Q2 25
8.7%
0.0%
Q1 25
12.4%
0.0%
Q4 24
0.2%
Q3 24
10.2%
0.0%
Q2 24
8.6%
0.1%
Q1 24
1.7%
0.0%
Cash Conversion
LAB
LAB
WHG
WHG
Q4 25
10.29×
Q3 25
2.29×
Q2 25
7.08×
Q1 25
-10.25×
Q4 24
5.69×
Q3 24
Q2 24
Q1 24
162.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

WHG
WHG

Advisory$21.0M78%
Fiduciary And Trust$5.6M21%

Related Comparisons